Raji Patil
Research Subjects
Raji Patil has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Debraj Shome
Department of Facial Plastic Surgery and Facial Cosmetic Surgery, The Esthetic Clinics (TEC ® ), Mumbai, India
13 shared publications - Rinky Kapoor
Department of Dermatology, Cosmetic Dermatology & Dermato- Surgery, The Esthetic Clinics (TEC ® ), Mumbai, India
13 shared publications - Mamata Mishra
Department of Research, The Esthetic Clinics Clinical Research Organization (TECCRO), Mumbai, India
5 shared publications - Debalina Bose
Advanced Technology Development Centre, Indian Institute of Technology Kharagpur, Kharagpur, India
4 shared publications - Depti Bellani
Department of Medical Affairs, Esthetic Creations International Pvt. Ltd. (ECIPL), Mumbai, India
4 shared publications - Varad Rajendra Saptarshi
Resident, Department of Oral & Maxillofacial Surgery, MGM Dental College & Hospital, Navi Mumbai, Maharashtra, India
4 shared publications
Latest Publications
- 5 November 2026
- Published by Taylor & Francis in Drug Metabolism Reviews
- p. 1-21
Personalized minoxidil therapy in androgenetic alopecia: from SULT1A1 biomarkers to precision clinical management
1. IntroductionAndrogenetic alopecia (AGA) is the most common cause of chronic progressive hair loss in both genders and is still one of the most common causes of consultation in dermatology. Altho...
- 5 November 2026
- Published by Taylor & Francis in Drug Metabolism Reviews
- p. 1-21
Personalized minoxidil therapy in androgenetic alopecia: from SULT1A1 biomarkers to precision clinical management
1. IntroductionAndrogenetic alopecia (AGA) is the most common cause of chronic progressive hair loss in both genders and is still one of the most common causes of consultation in dermatology. Altho...
- 24 October 2026
- Published by Springer Nature in Cell Biochemistry and Biophysics
Network (Cross‑Pathway) Engineered Organization: A Testable Framework for Configuring Regenerative Signalling in the Hair Follicle Niche
Hair follicle regeneration is commonly interpreted through individual pathways, cell populations, or classes of pro-growth interventions. Although these approaches have established the importance of hair follicle stem cells, dermal papilla cells, immune populations, extracellular matrix, and vascular-lymphatic niches, they provide limited guidance for how multiple regenerative inputs should be configured when designing an intervention. We propose Network (Cross‑Pathway) Engineered Organization as a translational design framework rather than as a replacement for established hair follicle niche biology. The framework defines an intervention through four linked, experimentally manipulable dimensions: composition, topology, temporal structure, and coupling. The framework predicts that interventions matched for total signal exposure may generate distinct regenerative outcomes when their architectural configuration differs. It further proposes that clinic-based induction and home-based maintenance can be studied as temporally coupled components of a single protocol-level signalling configuration. The framework is falsifiable if manipulating signal ratio, localization, sequencing, or kinetics does not alter molecular, cellular, or phenotypic outcomes after total dose and baseline niche state are controlled. By specifying intervention variables, comparators, and testable predictions, this article connects descriptive hair follicle biology with experimentally tractable design principles for regenerative biology.
- 24 October 2026
- Published by Springer Nature in Cell Biochemistry and Biophysics
Network (Cross‑Pathway) Engineered Organization: A Testable Framework for Configuring Regenerative Signalling in the Hair Follicle Niche
Hair follicle regeneration is commonly interpreted through individual pathways, cell populations, or classes of pro-growth interventions. Although these approaches have established the importance of hair follicle stem cells, dermal papilla cells, immune populations, extracellular matrix, and vascular-lymphatic niches, they provide limited guidance for how multiple regenerative inputs should be configured when designing an intervention. We propose Network (Cross‑Pathway) Engineered Organization as a translational design framework rather than as a replacement for established hair follicle niche biology. The framework defines an intervention through four linked, experimentally manipulable dimensions: composition, topology, temporal structure, and coupling. The framework predicts that interventions matched for total signal exposure may generate distinct regenerative outcomes when their architectural configuration differs. It further proposes that clinic-based induction and home-based maintenance can be studied as temporally coupled components of a single protocol-level signalling configuration. The framework is falsifiable if manipulating signal ratio, localization, sequencing, or kinetics does not alter molecular, cellular, or phenotypic outcomes after total dose and baseline niche state are controlled. By specifying intervention variables, comparators, and testable predictions, this article connects descriptive hair follicle biology with experimentally tractable design principles for regenerative biology.
- 3 September 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (8) , 3832-3834
Beyond Growth Factor Abundance: Why Hair Regeneration Needs Pathway-Oriented Design?
- 3 September 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (8) , 3832-3834
Beyond Growth Factor Abundance: Why Hair Regeneration Needs Pathway-Oriented Design?
- Open Access
- 24 July 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1) , 260
Beyond conventional PRP: a rationale for bioengineered, growth-factor-defined platelet mimetics in alopecia—the precision re-engineered efficacy optimization framework
- 24 July 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1) , 260
Open AccessBeyond conventional PRP: a rationale for bioengineered, growth-factor-defined platelet mimetics in alopecia—the precision re-engineered efficacy optimization framework
- 9 May 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (5) , 2649-2651
“Hair Follicle Stem Cells and their Lymphatic Niche: An Overlooked Axis in Cutaneous Regeneration”
- 9 May 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (5) , 2649-2651
“Hair Follicle Stem Cells and their Lymphatic Niche: An Overlooked Axis in Cutaneous Regeneration”
- 20 April 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (5) , 2628-2631
Activation of Bulge Stem Cells through Mechano-Stimulation and ECM Remodeling: Emerging Paradigms in Hair Follicle Regeneration
- 20 April 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (5) , 2628-2631
Activation of Bulge Stem Cells through Mechano-Stimulation and ECM Remodeling: Emerging Paradigms in Hair Follicle Regeneration
- 30 January 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (3) , 1511-1514
Reactive Oxygen Species and Hair Follicle Stem Cell Dysfunction
- 30 January 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (3) , 1511-1514
Reactive Oxygen Species and Hair Follicle Stem Cell Dysfunction
- 21 January 2026
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 40 (2) , 129-144
Beyond the Follicle: A Narrative Review on How Systemic Diseases and Drugs Affect Alopecia
Alopecia is a multifactorial condition resulting from the convergence of systemic pathologies, pharmacologic exposures, genetic predispositions, and environmental factors. Among these, systemic diseases and medications play a prominent role by initiating biological cascades that disrupt follicular integrity. Systemic diseases and medications disrupt follicular homeostasis via mechanisms such as inflammation, oxidative stress, hormonal imbalance, and immune dysregulation. Endocrine disorders, metabolic syndromes, and nutritional deficiencies impair follicular function, while chemotherapeutics, antifungals, anticoagulants, and hormonal agents further compromise follicular cycling and stem cell viability. Understanding these mechanistic pathways is essential for predicting and mitigating drug-associated alopecia and informing targeted interventions. Precision medicine approaches that address systemic drivers while optimizing pharmacologic regimens are critical to preserving follicular integrity. Current treatments like minoxidil, platelet-rich plasma, and surgical restoration provide symptomatic relief but often fail to achieve lasting results. In contrast, emerging molecular therapies, including bioengineered exosomes, stem cell applications, and peptide-based formulations that target key signalling pathways and growth factors, hold promise for more regenerative and sustained hair restoration outcomes. Given the condition’s complexity, a multidisciplinary framework integrating dermatology, endocrinology, immunology, and pharmacology is essential. Cross-specialty collaboration will be pivotal for advancing individualised, mechanism-driven care. Ultimately, accurate etiologic diagnosis remains the cornerstone of effective, tailored treatment strategies.
- 21 January 2026
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 40 (2) , 129-144
Beyond the Follicle: A Narrative Review on How Systemic Diseases and Drugs Affect Alopecia
Alopecia is a multifactorial condition resulting from the convergence of systemic pathologies, pharmacologic exposures, genetic predispositions, and environmental factors. Among these, systemic diseases and medications play a prominent role by initiating biological cascades that disrupt follicular integrity. Systemic diseases and medications disrupt follicular homeostasis via mechanisms such as inflammation, oxidative stress, hormonal imbalance, and immune dysregulation. Endocrine disorders, metabolic syndromes, and nutritional deficiencies impair follicular function, while chemotherapeutics, antifungals, anticoagulants, and hormonal agents further compromise follicular cycling and stem cell viability. Understanding these mechanistic pathways is essential for predicting and mitigating drug-associated alopecia and informing targeted interventions. Precision medicine approaches that address systemic drivers while optimizing pharmacologic regimens are critical to preserving follicular integrity. Current treatments like minoxidil, platelet-rich plasma, and surgical restoration provide symptomatic relief but often fail to achieve lasting results. In contrast, emerging molecular therapies, including bioengineered exosomes, stem cell applications, and peptide-based formulations that target key signalling pathways and growth factors, hold promise for more regenerative and sustained hair restoration outcomes. Given the condition’s complexity, a multidisciplinary framework integrating dermatology, endocrinology, immunology, and pharmacology is essential. Cross-specialty collaboration will be pivotal for advancing individualised, mechanism-driven care. Ultimately, accurate etiologic diagnosis remains the cornerstone of effective, tailored treatment strategies.